Tumor size, but not consolidation‐to‐tumor ratio, is an independent prognostic factor for part‐solid clinical T1 non‐small cell lung cancer. Issue 6 (28th December 2022)

• Record Type: Journal Article
• Authors: Li, Zhihua; Xu, Wenzheng; Gu, Tianhao; Cao, Xincen; Wu, Weibing; Chen, Liang
• Is Part Of: Thoracic cancer. Volume 14:Issue 6(2023)
• Page Start: 602
• Page End: 611
• Publication Date: 2022-12-28
• Subjects: consolidation‐to‐tumor ratio -- ground‐glass opacity -- non‐small cell lung cancer -- part‐solid nodules -- tumor size; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.14788
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: Background: Tumor size and consolidation‐to‐tumor ratio (CTR) are crucial for non–small cell lung cancer (NSCLC) prognosis. However, the optimal CTR cutoff remains unclear. Whether tumor size and CTR are independent prognostic factors for part‐solid NSCLC is under debate. Here, we aimed to evaluate the prognostic impacts of CTR and tumor size on NSCLC, especially on part‐solid NSCLC. Methods: We reviewed 1366 clinical T1 NSCLC patients who underwent surgical treatment. Log‐rank test and Cox regression analyses were adopted for prognostic evaluation. The "surv_cutpoint" function was used to identify the optimal CTR and tumor size cutoff values. Results: There were 416, 510, and 440 subjects with pure ground‐glass opacity (pGGO), part‐solid, and pure solid nodules. The 5‐year overall survival (disease‐free survival) for patients with pGGO, part‐solid, and pure solid nodules were 99.5% (99.5%), 97.3% (95.8%), and 90.4% (78.9%), respectively. Multivariate Cox regression analysis indicated that CTR was an independent prognostic factor for the whole patients, and the optimal CTR cutoff was 0.99. However, for part‐solid NSCLC, CTR was not independently associated with survival, even if categorized by the optimal cutoffs. The predicted optimal cutoffs of total tumor size and solid component size were 2.4 and 1.4 cm for part‐solid NSCLC. Total tumor size (HR = 6.21, 95% CI: 1.58–24.34, p = 0.009) and solid component size (HR = 2.27, 95% CI: 1.04–5.92, p = 0.045) grouped by the cutoffs were significantly associated with part‐solid NSCLC prognosis. Conclusions: CTR was an independent prognostic factor for the whole NSCLC, but not for the part‐solid NSCLC. Tumor size was still meaningful for part‐solid NSCLC. Abstract : CTR (consolidation‐to‐tumor ratio) was an independent prognostic factor for the whole clinical T1 NSCLC (the optimal CTR cutoff was 0.99), but not for the part‐solid NSCLC. Total tumor size and solid component size were still meaningful for the prognosis of part‐solid NSCLC.